

diastereomer.

6. (Amended) A pharmaceutical composition comprising a compound of formula (1) described in claim 1[.] in association with a pharmaceutically acceptable carrier.

13. (Amended) [A compound of claim 1 which is the] 2,2' [(E)-4-Octenedioylbis(oxytrimethylene)]bis[1R,2R-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinum] cation in association with a pharmaceutically acceptable anion.

14. (Amended) [A compound of claim 1 which is the] (E)-(1R,1'R,2R,2'S)-2,2'-[4-Octenedioylbis(oxytrimethylene)]bis[1,2,3,4-tetrahydro-6,7-[dimethoxyoxy]dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium] cation in association with a pharmaceutically acceptable anion.

15. (Amended) [A compound of claim 1 which is the] 2,2'-[(E)-4-Octenedioylbis(oxytrimethylene)]bis[(1R,2S)-1,2,3,4-tetrahydro-6-,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium] cation in association with a pharmaceutically acceptable anion.

Please add the following claims:

19. 2,2' [(E)-4-Octenedioylbis(oxytrimethylene)]bis[1R,2R-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinum] dichloride.

Serial No. 756,025

20. (E)-(1R, 1'R, 2R, 2'S)-2,2'-[4-Octenedioylbis(oxytrimethylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzylisoquinolinium] dichloride.

21. 2,2'-[(E)-4-Octenedioylbis(oxytrimethylene)]bis[(1R, 2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium] dichloride.

22. A method for producing muscle relaxation in a mammal which comprises parenterally administering to a mammal an effective muscle relaxant amount of one or more of the compounds of claims 19, 20 or 21.

23. A sterile pharmaceutical composition comprising one or more of the compounds of claims 19, 20, or 21 and a pharmaceutically acceptable solvent carrier therefor.

Please change the title to ISOQUINOLINIUM COMPOUNDS AND USE AS MUSCLE RELAXANTS.

REMARKS

With regard to the claims, claim 1 has been amended so that the double bond as shown below can be seen clearly



in the compound of formula I.

With regard to claims 13 to 15 rejected as being substantial duplicates of claim 1, it is pointed out these are E compounds and ~~R AND S~~ isomers are ^{claimed} and thus these claims are more